These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 30005555

  • 1. Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy.
    Tompkins BA, Rieger AC, Florea V, Banerjee MN, Natsumeda M, Nigh ED, Landin AM, Rodriguez GM, Hatzistergos KE, Schulman IH, Hare JM.
    J Am Heart Assoc; 2018 Jul 12; 7(14):. PubMed ID: 30005555
    [Abstract] [Full Text] [Related]

  • 2. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
    Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A.
    JAMA; 2012 Dec 12; 308(22):2369-79. PubMed ID: 23117550
    [Abstract] [Full Text] [Related]

  • 3. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.
    Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, Ghersin E, Soto V, Lopera G, Miki R, Willens H, Hendel R, Mitrani R, Pattany P, Feigenbaum G, Oskouei B, Byrnes J, Lowery MH, Sierra J, Pujol MV, Delgado C, Gonzalez PJ, Rodriguez JE, Bagno LL, Rouy D, Altman P, Foo CW, da Silva J, Anderson E, Schwarz R, Mendizabal A, Hare JM.
    JAMA; 2014 Jan 01; 311(1):62-73. PubMed ID: 24247587
    [Abstract] [Full Text] [Related]

  • 4. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.
    Hare JM, DiFede DL, Rieger AC, Florea V, Landin AM, El-Khorazaty J, Khan A, Mushtaq M, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Alfonso CE, Valasaki K, Pujol MV, Golpanian S, Ghersin E, Fishman JE, Pattany P, Gomes SA, Delgado C, Miki R, Abuzeid F, Vidro-Casiano M, Premer C, Medina A, Porras V, Hatzistergos KE, Anderson E, Mendizabal A, Mitrani R, Heldman AW.
    J Am Coll Cardiol; 2017 Feb 07; 69(5):526-537. PubMed ID: 27856208
    [Abstract] [Full Text] [Related]

  • 5. The Effect of Transendocardial Stem Cell Injection on Erectile Function in Men With Cardiomyopathy: Results From the TRIDENT, POSEIDON, and TAC-HFT Trials.
    Ory J, Saltzman RG, Blachman-Braun R, Dadoun S, DiFede DL, Premer C, Hurwitz B, Hare JM, Ramasamy R.
    J Sex Med; 2020 Apr 07; 17(4):695-701. PubMed ID: 32059936
    [Abstract] [Full Text] [Related]

  • 6. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study).
    Florea V, Rieger AC, DiFede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, Tompkins BA, Khan A, Schulman IH, Landin AM, Mushtaq M, Golpanian S, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Valasaki K, Pujol MV, Ghersin E, Miki R, Delgado C, Abuzeid F, Vidro-Casiano M, Saltzman RG, DaFonseca D, Caceres LV, Ramdas KN, Mendizabal A, Heldman AW, Mitrani RD, Hare JM.
    Circ Res; 2017 Nov 10; 121(11):1279-1290. PubMed ID: 28923793
    [Abstract] [Full Text] [Related]

  • 7. Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention.
    Streitner F, Kuschyk J, Dietrich C, Mahl E, Streitner I, Doesch C, Veltmann C, Schimpf R, Wolpert C, Borggrefe M.
    Clin Cardiol; 2011 Oct 10; 34(10):604-9. PubMed ID: 21887690
    [Abstract] [Full Text] [Related]

  • 8. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy.
    Mushtaq M, DiFede DL, Golpanian S, Khan A, Gomes SA, Mendizabal A, Heldman AW, Hare JM.
    J Cardiovasc Transl Res; 2014 Dec 10; 7(9):769-80. PubMed ID: 25354998
    [Abstract] [Full Text] [Related]

  • 9. Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients.
    Golpanian S, El-Khorazaty J, Mendizabal A, DiFede DL, Suncion VY, Karantalis V, Fishman JE, Ghersin E, Balkan W, Hare JM.
    J Am Coll Cardiol; 2015 Jan 20; 65(2):125-32. PubMed ID: 25593053
    [Abstract] [Full Text] [Related]

  • 10. Effects of surgical ventricular reconstruction and mitral complex reconstruction on cardiac oxidative metabolism and efficiency in nonischemic and ischemic dilated cardiomyopathy.
    Sugiki T, Naya M, Manabe O, Wakasa S, Kubota S, Chiba S, Iwano H, Yamada S, Yoshinaga K, Tamaki N, Tsutsui H, Matsui Y.
    JACC Cardiovasc Imaging; 2011 Jul 20; 4(7):762-70. PubMed ID: 21757167
    [Abstract] [Full Text] [Related]

  • 11. Clinical Outcomes of Autologous Stem Cell-Patch Implantation for Patients With Heart Failure With Nonischemic Dilated Cardiomyopathy.
    Domae K, Miyagawa S, Yoshikawa Y, Fukushima S, Hata H, Saito S, Kainuma S, Kashiyama N, Iseoka H, Ito E, Harada A, Takeda M, Sakata Y, Toda K, Pak K, Yamada T, Sawa Y.
    J Am Heart Assoc; 2021 Jul 06; 10(13):e008649. PubMed ID: 34212772
    [Abstract] [Full Text] [Related]

  • 12. Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy.
    McLeod CJ, Shen WK, Rea RF, Friedman PA, Hayes DL, Wokhlu A, Webster TL, Wiste HJ, Hodge DO, Bradley DJ, Hammill SC, Packer DL, Cha YM.
    Heart Rhythm; 2011 Mar 06; 8(3):377-82. PubMed ID: 21070886
    [Abstract] [Full Text] [Related]

  • 13. Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy.
    Hamada T, Kubo T, Kitaoka H, Hirota T, Hoshikawa E, Hayato K, Shimizu Y, Okawa M, Yamasaki N, Matsumura Y, Yabe T, Takata J, Doi YL.
    Clin Cardiol; 2010 Jul 06; 33(7):E24-8. PubMed ID: 20641106
    [Abstract] [Full Text] [Related]

  • 14. The impact of patient sex on the response to intramyocardial mesenchymal stem cell administration in patients with non-ischaemic dilated cardiomyopathy.
    Florea V, Rieger AC, Natsumeda M, Tompkins BA, Banerjee MN, Schulman IH, Premer C, Khan A, Valasaki K, Heidecker B, Mantero A, Balkan W, Mitrani RD, Hare JM.
    Cardiovasc Res; 2020 Nov 01; 116(13):2131-2141. PubMed ID: 32053144
    [Abstract] [Full Text] [Related]

  • 15. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy.
    Trachtenberg B, Velazquez DL, Williams AR, McNiece I, Fishman J, Nguyen K, Rouy D, Altman P, Schwarz R, Mendizabal A, Oskouei B, Byrnes J, Soto V, Tracy M, Zambrano JP, Heldman AW, Hare JM.
    Am Heart J; 2011 Mar 01; 161(3):487-93. PubMed ID: 21392602
    [Abstract] [Full Text] [Related]

  • 16. Left ventricular reverse remodeling in dilated cardiomyopathy- maintained subclinical myocardial systolic and diastolic dysfunction.
    Amorim S, Rodrigues J, Campelo M, Moura B, Martins E, Macedo F, Silva-Cardoso J, Maciel MJ.
    Int J Cardiovasc Imaging; 2017 May 01; 33(5):605-613. PubMed ID: 28013418
    [Abstract] [Full Text] [Related]

  • 17. Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit+ Cardiac Stem Cells As Regenerative Therapy for Heart Failure).
    Bolli R, Hare JM, March KL, Pepine CJ, Willerson JT, Perin EC, Yang PC, Henry TD, Traverse JH, Mitrani RD, Khan A, Hernandez-Schulman I, Taylor DA, DiFede DL, Lima JAC, Chugh A, Loughran J, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Moyé L, Ebert RF, Simari RD, Cardiovascular Cell Therapy Research Network (CCTRN).
    Circ Res; 2018 Jun 08; 122(12):1703-1715. PubMed ID: 29703749
    [Abstract] [Full Text] [Related]

  • 18. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial.
    Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, East C, Remmers AE, Goodrich J, Desai AS, Recker D, DeMaria A, ixCELL-DCM Investigators.
    Lancet; 2016 Jun 11; 387(10036):2412-21. PubMed ID: 27059887
    [Abstract] [Full Text] [Related]

  • 19. Electroanatomic Properties of the Myocardium Predict Response to CD34+ Cell Therapy in Patients With Ischemic and Nonischemic Heart Failure.
    Zemljic G, Poglajen G, Sever M, Cukjati M, Frljak S, Androcec V, Cernelc P, Haddad F, Vrtovec B.
    J Card Fail; 2017 Feb 11; 23(2):153-160. PubMed ID: 27523610
    [Abstract] [Full Text] [Related]

  • 20. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.
    Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD, Cardiovascular Cell Therapy Research Network (CCTRN).
    JAMA; 2012 Apr 25; 307(16):1717-26. PubMed ID: 22447880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.